Individuals who are hospitalized for the skin conditions of Stevens-Johnson syndrome and toxic epidermal necrolysis appear to have a high risk of recurrence, according to a new study.
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening conditions that develop primarily as responses to drugs, and result in extensive epidermal detachment (upper layers of the skin detach from the lower layers). Recurrence has been reported in isolated cases, and the overall risk of recurrence has been unknown, according to background information in the article.
Yaron Finkelstein, M.D., of the Hospital for Sick Children, Toronto, and colleagues conducted a study that included data of all Ontario residents hospitalized for a first episode of Stevens-Johnson syndrome or toxic epidermal necrolysis between April 2002 and March 2011. Patients were followed up from admission until March 31, 2012, or death. The researchers identified 708 individuals hospitalized for a first episode of SJS (n = 567) or TEN (n = 141), including 127 (17.9 percent) children younger than 18 years.
Forty-two patients (7.2 percent) were hospitalized for a subsequent episode of Stevens-Johnson syndrome or toxic epidermal necrolysis. Eight patients (1.4 percent) experienced multiple recurrences. The median time to first recurrence was 315 days.
“In light of the reported incidence of SJS and TEN in the general population (1.0-7.2 cases/1 million individuals/year), the observed recurrence risk in our study (>7 percent) is several thousand-fold higher than would be expected if subsequent episodes were probabilistically independent of the first SJS or TEN episode. We speculate that this increased risk reflects individual susceptibility. Genetic predisposition has been identified for several medications in association with specific genotypes …” the authors write.
“… these findings are relevant to physicians who care for patients with a history of SJS or TEN. Because most such episodes are drug-induced, the high risk of recurrence should be recognized, and the benefits of drug therapy weighed carefully against the potential risks. This is particularly true for drugs commonly associated with the development of these frequently fatal conditions.”
Citation: Yaron Finkelstein MD, ABCP(Dip), Erin M. Macdonald MSc, Ping Li PhD, Janine R. Hutson MD, MSc, David N. Juurlink MD, PhD, 'Recurrence and Mortality Following Severe Cutaneous Adverse Reactions', JAMA. 2014;311(21):2231-2232. doi:10.1001/jama.2014.839
- PHYSICAL SCIENCES
- EARTH SCIENCES
- LIFE SCIENCES
- SOCIAL SCIENCES
Subscribe to the newsletter
Stay in touch with the scientific world!
Know Science And Want To Write?
- Why An Extra Planet Can't Be Hidden Behind The Sun Or Above The South Pole
- Lichen: Apparently Happy Couple Really A Threesome
- The Daily Physics Problem - 2
- The Daily Physics Problem - 1
- US Could Feed Twice As Many People - If Only Elites Eat Meat
- People Estimate Their Own Abilities Based On Others' Performance
- Hugh Hefner's Wife Was Not Poisoned By Breast Implants
- "Hi Lumo,sorry but you should think a bit more about the task that the selection committee has in..."
- "Thanks, glad to have helped. Yes of course, it is up to people to believe what they want to believe..."
- "Oh, sorry I should have added a TL:DR. Have done so now:I am skeptical about any of ideas about..."
- "Thanks for the nice and in detail article Mr.Walker. I some times feel pity on those whose motive..."
- "Thanks, glad to have helped :)...."
- Unusual new zoantharian species is the first described solitary species in over 100 years
- Scientists develop painless and inexpensive microneedle system to monitor drugs
- Parasite proteins prompt immune system to fight off ovarian tumors in mice
- Behavioral activation as effective as CBT for depression, at lower cost
- The Lancet: Simpler, cheaper psychological treatment as effective as cognitive behavioural therapy for treating depression